Screener Summaries Updates Institutions Sign In More Updates › Mergers & Acquisitions › SEER Mergers & Acquisitions · Jul 2, 2026
Seer, Inc. announced the receipt of an unsolicited, non-binding proposal from its Chair and CEO, Omid Farokhzad, M.D.… SEER Seer, Inc.
Seer, Inc. announced the receipt of an unsolicited, non-binding proposal from its Chair and CEO, Omid Farokhzad, M.D., to acquire all outstanding Class A common stock for $2.45 per share in cash plus two separate contingent value rights. Seer, Inc. is a biotechnology company providing proteomics-based solutions for biological research and clinical diagnostics.
More from Seer, Inc. Seer rejects unsolicited $2.55-per-share acquisition proposal from Radoff-JEC Group Oct 29, 2026 On September 14, 2026, David Horn resigned as President, CFO, and Treasurer of Seer, Inc., effective October 1, 2026… Sep 18, 2026 Seer, Inc. reported second quarter 2026 financial results with revenue of $3.1 million, a 23% decrease from the prior… Aug 11, 2026 Seer, Inc. confirmed receipt of two revised, non-binding acquisition proposals to acquire all outstanding Class A… Jul 31, 2026 On July 20, 2026, Seer, Inc. announced that a Special Committee of its Board of Directors unanimously rejected an… Jul 20, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
